Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Hits Anti-Infective Target With Arrow Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.

You may also be interested in...



Eyeing The Future: AstraZeneca Farms Out Compounds To Ocular Specialist Alcon

Alcon's now-tenuous relationship with Novartis is unlikely to affect the new five-year research agreement with AstraZeneca.

Eyeing The Future: AstraZeneca Farms Out Compounds To Ocular Specialist Alcon

Alcon's now-tenuous relationship with Novartis is unlikely to affect the new five-year research agreement with AstraZeneca.

Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate

Companies plan IND filing for their next novel NS4A antagonist in the first or second quarter of 2008.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel